Scancell founder says the company is ready to commercialise novel medicines to counteract cancer. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOncimmune Regulatory News (ONC)

Share Price Information for Oncimmune (ONC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 14.35
Bid: 14.00
Ask: 14.90
Change: 0.00 (0.00%)
Spread: 0.90 (6.429%)
Open: 14.35
High: 0.00
Low: 0.00
Prev. Close: 14.35
ONC Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Grant of options

8 Nov 2016 18:25

RNS Number : 6778O
Oncimmune Holdings PLC
08 November 2016
 

8 November 2016

 

Oncimmune Holdings plc

("Oncimmune" or the "Company")

 

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PDMR AND PERSONS CLOSELY ASSOCIATED WITH THEM

 

Oncimmune Holdings plc (AIM: ONC.L), a leading early cancer detection company developing and commercialising its proprietary EarlyCDT® platform technology, today announces that on 8 November 2016, options over ordinary shares of the Company were awarded to certain Directors and certain PDMRs under the Company's 2016 Share Option Plan (an amalgamation of the Company's 2005 and 2007 Share Option Plans) as follows.

 

Name

Position

Number of share options awarded

Option exercise price per share (pence)

Percentage of issued share capital (%)

Meinhard Schmidt

Non-executive Chairman

120,370

108

0.236

Geoffrey Hamilton-Fairley

Chief Executive Officer

528,273

1

1.035

119,875

108

0.235

Andrew Millet

Chief Financial Officer

92,593

108

0.181

Andrea Murray

Chief Operational Scientist

41,667

108

0.082

Maarten Brusse

Chief Commercial Officer

74,074

108

0.145

 

The options are subject to the rules of the 2016 Share Option Plan and vest in five equal annual parts, the first fifth vesting on 7 November 2017 and each year thereafter for a further four years, subject to continued employment. Unless otherwise indicated in the table above, the options are exercisable at 108 pence, being the mid-market closing price of the Company's ordinary shares on 7 November 2016

 

For further information:

 

Oncimmune Holdings plc

Geoffrey Hamilton-Fairley, Chief Executive Officer

contact@oncimmune.co.uk

 

Zeus Capital Limited (Nominated Adviser and Broker)

Phil Walker, Giles Balleny, Dominic Wilson

+44 (0) 203 829 5000

 

Media enquiries:

Consilium Strategic Communications

Chris Gardner, Mary-Jane Elliott, Matthew Neal, Lindsey Neville

oncimmune@consilium-comms.com

+44 (0) 20 3709 5708

 

 

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

 

Meinhard Schmidt

2

Reason for the notification

a)

Position/status

 

Non-Executive Chairman, Director

b)

Initial notification/Amendment

 

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Oncimmune Holdings plc

b)

LEI

N/A

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

 

Identification code

options over 1p ordinary shares - 2016 Share Option Plan

 

 

ISIN GB00BYQ94H38

b)

Nature of the transaction

 

Grant of options over ordinary shares

c)

Price(s) and volume(s)

 

 

Price(s)

Volume(s)

N/A

120,370

d)

Aggregated information

 

Price(s)

Volume(s)

N/A

120,370

e)

Date of the transaction

 

8 November 2016

f)

Place of the transaction

 

 

N/A

 

 

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

 

Geoffrey Hamilton-Fairley

2

Reason for the notification

a)

Position/status

 

Chief Executive Officer

b)

Initial notification/Amendment

 

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Oncimmune Holdings Plc

b)

LEI

N/A

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

 

Identification code

options over 1p ordinary shares - 2016 Share Option Plan

 

ISIN GB00BYQ94H38

b)

Nature of the transaction

 

Grant of options over ordinary shares

c)

Price(s) and volume(s)

 

 

Price(s)

Volume(s)

N/A

528,273

N/A

119.875

d)

Aggregated information

 

Price(s)

Volume(s)

N/A

648,148

e)

Date of the transaction

 

8 November 2016

f)

Place of the transaction

 

 

N/A

 

 

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

 

Andrew Millet

2

Reason for the notification

a)

Position/status

 

Chief Financial Officer

b)

Initial notification/Amendment

 

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Oncimmune Holdings Plc

b)

LEI

N/A

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

 

Identification code

options over 1p ordinary shares - 2016 Share Option Plan

 

ISIN GB00BYQ94H38

b)

Nature of the transaction

 

Grant of options over ordinary shares

c)

Price(s) and volume(s)

 

 

Price(s)

Volume(s)

N/A

92,593

d)

Aggregated information

 

Price(s)

Volume(s)

N/A

92,593

e)

Date of the transaction

 

8 November 2016

f)

Place of the transaction

 

 

N/A

 

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

 

Andrea Murray

2

Reason for the notification

a)

Position/status

 

Chief Operational Scientist and PDMR

b)

Initial notification/Amendment

 

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Oncimmune Holdings Plc

b)

LEI

N/A

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

 

Identification code

options over 1p ordinary shares - 2016 Share Option Plan

 

ISIN GB00BYQ94H38

b)

Nature of the transaction

 

Grant of options over ordinary shares

c)

Price(s) and volume(s)

 

 

Price(s)

Volume(s)

N/A

41,667

d)

Aggregated information

 

Price(s)

Volume(s)

N/A

41,667

e)

Date of the transaction

 

8 November 2016

f)

Place of the transaction

 

 

N/A

 

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

 

Maarten Brusse

2

Reason for the notification

a)

Position/status

 

Chief Commercial Officer and PDMR

b)

Initial notification/Amendment

 

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Oncimmune Holdings Plc

b)

LEI

N/A

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

 

Identification code

options over 1p ordinary shares - 2016 Share Option Plan

 

ISIN GB00BYQ94H38

b)

Nature of the transaction

 

Grant of options over ordinary shares

c)

Price(s) and volume(s)

 

 

Price(s)

Volume(s)

N/A

74,074

d)

Aggregated information

 

Price(s)

Volume(s)

N/A

74,074

e)

Date of the transaction

 

8 November 2016

f)

Place of the transaction

 

 

N/A

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
DSHBIBDBSDGBGLI
Date   Source Headline
1st Oct 20187:00 amRNSBusiness Update
28th Sep 20187:00 amRNSAppointment of Non-Executive Director
25th Sep 20183:45 pmRNSIASLC World Conference on Lung Cancer Presentation
25th Sep 20187:00 amRNSGrant of options
24th Sep 20187:00 amRNSBoard Change
13th Sep 20187:00 amRNSAppointment of Marco Casarin as General Manager
26th Jul 201812:33 pmRNSNotification & Public Disclosure of a Transaction
4th Jun 20187:38 amRNSBusiness Update
24th May 20187:00 amRNSNew Distribution Agreements for EarlyCDT®-Lung Kit
23rd May 20187:00 amRNSOncimmune Publishes Study in PLOS ONE
14th May 20187:00 amRNSOncimmune Launches EarlyCDT®-Liver Test in the US
23rd Apr 20187:00 amRNSPDMR Notification
11th Apr 20182:01 pmRNSHolding(s) in Company
27th Mar 20188:00 amRNSFinal tranche of £10m equity investment
27th Mar 20187:00 amRNSAppointment of Dr Adam Hill as CMO and CSO
13th Feb 20187:00 amRNSInterim Results for the half year ended 30 Nov 17
5th Feb 20187:01 amRNSUniversity of Nottingham share sale
5th Feb 20187:00 amRNSHoldings in Company
2nd Feb 20184:45 pmRNSTotal Voting Rights
29th Jan 20187:00 amRNSFirst tranche of £10m equity investment
23rd Jan 20187:00 amRNSBusiness Update and Notice of Interim Results
22nd Jan 201811:21 amRNSResult of General Meeting
9th Jan 20187:00 amRNSAppointment of Non-Executive Director
4th Jan 20187:30 amRNSNotice of General Meeting
2nd Jan 20187:00 amRNSFramework agreement, licence and £10m investment
21st Dec 20177:00 amRNSValidation of EarlyCDT®-Liver test
30th Nov 20173:53 pmRNSHolding(s) in Company
29th Nov 20179:55 amRNSResult of AGM
27th Nov 20177:00 amRNSAppointment of joint brokers
24th Nov 20177:00 amRNSSatisfaction of Delayed Completion Placing
22nd Nov 20177:00 amRNSDeadline extended for Delayed Completion Placing
16th Nov 20177:00 amRNSDistribution agreement signed for Iran
9th Nov 20177:00 amRNSLaunch of "Finger Stick" Sample Collection
3rd Nov 20177:00 amRNSAnnual Report and Accounts and AGM Notification
27th Oct 201710:32 amRNSDirector/PDMR Shareholding
20th Oct 20177:00 amRNSResults for the year ended 31 May 2017
18th Oct 20177:00 amRNSDistribution Agreement in Poland
10th Oct 201711:15 amRNSHoldings in Company
10th Oct 20177:00 amRNSNotice of Results
27th Sep 20172:11 pmRNSSuccessful £5.0m placing
26th Sep 20175:12 pmRNSProposed placing to raise up to £5.3m
19th Sep 20177:00 amRNSEarlyCDT®-Lung Kit Distribution Agreements
18th Sep 20177:00 amRNSData presented at the 11th Annual ILCA
14th Sep 20177:00 amRNSBusiness Update
29th Aug 20177:00 amRNSOncimmune and Scancell Present Data
20th Jul 20171:59 pmRNSExercise of Options & 2007 Share Option Scheme
7th Jul 20177:00 amRNSHolding(s) in Company
5th Jun 20177:00 amRNSBusiness Update and New Distribution Agreements
31st May 20177:00 amRNSCE Mark for EarlyCDT-Lung Kit
17th May 20177:00 amRNSGRANT OF OPTIONS

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.